This content is from: Research
The 2014 All-America Research Team: Managed Care, No. 2: Joshua Raskin
Total appearances: 3
Team debut: 2002
Barclays analyst Joshua Raskin repeats at No. 2 on this roster and at runner-up on the Health Care Facilities list. He forecasts that U.S. managed care stocks will continue to outperform, as they did year to date through mid-September, rising 15.4 percent while the nations broad market gained 7.3 percent. Preferred names in the group include Aetna in Hartford, Connecticut, and St. Louiss Centene Corp. Aetnas May 2013 acquisition of Bethesda, Marylandbased Coventry Health Care continues to move along ahead of pace, and additional synergies are pushing guidance higher, notes Raskin. His $95 price objective for the stock represents a 15.7 percent upside to their value in mid-September. As for Centene, Raskin highlights the companys strong second-quarter results and managements modest boost to guidance for 2014. Most important, in this phase of above-average industry growth, the top line continues to exceed our estimates, and revenue guidance is up another 5 percent, he notes. Centene traded at $77.21 in mid-September, and he forecasts a rise to $96. Josh works harder than anyone to condense all of the health care service company regulatory filings into information I can use to make investment decisions, reports one admirer. He also delivers information on key trends, earnings releases and company announcements faster than anyone else on the Street, making it easier to come to timely investment decisions that can make or save money.